Biogen Inc. reported solid second-quarter financial results, including revenues of $2.9 billion – a 12 percent increase compared to the same period in 2015. The bigger news – at least to those outside its Cambridge, Mass., headquarters – was the revelation by CEO George Scangos at the outset of the company's earnings call that he will leave the company "sometime within the next few months," following "an orderly transition," to return to the West Coast, spend more time with family and "take on one more set of activities." Read More
LONDON – Cytox Ltd. today is launching a genetic biomarker test for Alzheimer's disease, which it says will enable the selection of amyloid-positive cohorts for clinical trials from amongst subjects who are pre-symptomatic or showing early signs of cognitive impairment. Read More
DURBAN, South Africa – In the early days of the AIDS epidemic, the life expectancy for those diagnosed with HIV was two years from the time of diagnosis. Read More
DUBLIN – Nextech Invest Ltd. missed the $100 million target it set for its Oncology Fund IV, closing with $64 million in the pot – enough to continue its focus on investing in high-quality firms focused on cancer. Read More
The EMA released a consultation paper Thursday as a next step in revising its 2007 guideline on first-in-human (FIH) clinical trials to enhance strategies to identify and mitigate risk for participants. Read More
Inflarx GmbH, of Jena, Germany, said it raised €31 million (US$34 million) in a series C round from new investors such as Staidson Hongkong Investment Co. Ltd., international industrial investors and family offices as well as existing investors. Read More
Cytodyn Inc., of Vancouver, Washington, said it submitted an application for FDA orphan status for PRO 140 (humanized monoclonal antibody to CCR5) for the pretreatment of HIV-1 infection in treatment-naïve adults who are awaiting drug resistance assay results to construct a highly active antiretroviral therapy regimen, a process that typically takes about two weeks. Cytodyn recently submitted a protocol for a phase IIb trial in treatment-naïve adults. Read More
Targazyme Inc., of San Diego, enrolled the first patient in a phase I/II TZ 101-treated regulatory T-cell study to evaluate the efficacy and safety in acute and chronic graft-vs.-host disease (GVHD) in stem cell transplants. Read More
